Prostatic Neoplasms
447
40
72
240
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
87 trials with published results (19%)
Research Maturity
240 completed trials (54% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.2%
59 terminated out of 447 trials
80.3%
-6.3% vs benchmark
13%
57 trials in Phase 3/4
36%
87 of 240 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 240 completed trials
Clinical Trials (447)
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Collection of Blood From Patients With Prostate Cancer
Hemodynamic Effects of Trendelenburg Position and Pneumoperitoneum in Urologic Robotic Surgery
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy